Skip Navigation

skip navigationNIDDK Home
NIDDK Reference Collection
Diet   Exercise   Health  
Home Page
-  

FAQ

Detailed Search

- -
NIDDK INFORMATION SERVICES
- -

Diabetes

Digestive Diseases

Endocrine and Metabolic Diseases

Hematologic Diseases

Kidney and Urologic Diseases

Weight-control Information Network

-
NIDDK EDUCATION
PROGRAMS

- -

National Diabetes Education Program

National Kidney Disease Education Program

-
- - -
NIDDK Home
-
Contact Us
-
New Search
-
Topic: Diabetes (DM)
Title: Switching from Insulin to Oral Sulfonylureas in Patients with Diabetes Due to Kir6.2 Mutations.
Author: Pearson, E.R., et al.
Source: New England Journal of Medicine. 355(5): 467-477. August 3, 2006.
Abstract: In diabetes patients diagnosed at six months of age or younger, approximately 30 to 58 percent of cases are caused by heterozygous activating mutations in KCNJ11, encoding the Kir6.2 subunit of the ATP-sensitive potassium channel. These patients present with ketoacidosis or severe hyperglycemia and are treated with insulin. This article reports on a study of glycemic control in 49 patients with Kir6.2 mutations who received appropriate doses of sulfonylureas. The authors also investigated, in smaller subgroups, the insulin secretory responses to intravenous and oral glucose, a mixed meal, and glucagon. A total of 44 patients (90 percent) successfully discontinued insulin after receiving sulfonylureas. Glycated hemoglobin levels improved in all patients who switched to sulfonylurea therapy. Improved glycemic control was sustained at one year. Sulfonylurea treatment increased insulin secretion, which was more highly stimulated by oral glucose or a mixed meal than by intravenous glucose. The authors conclude that sulfonylurea therapy is safe in the short term for patient with diabetes caused by KCNJ11 mutations and is probably more effective than insulin therapy. This pharmacogenetic response to sulfonylureas may result from the closing of the mutant ATP-sensitive potassium channels, thereby increasing insulin secretion in response to incretins and glucose metabolism. 4 figures. 1 table. 30 references.

Format: Journal Article
Language: English.
Major Keywords: Diabetes Mellitus. Genetics. Monogenic Diabetes. Drug Therapy. Pathology. Infants. Insulin.
Minor Keywords: Pharmacology. Patient Selection. Pancreas. Oral Hypoglycemic Agents. Sulfonylurea Compounds. Administration and Dosage. Glycosylated Hemoglobin. Blood Glucose.
Publication Number: DMJA12806.
Printer-Friendly Version | Return to Search Results
<-- previous record | next record -->

View NIDDK Publications | NIDDK Health Information | Contact Us

The NIDDK Reference Collection is a service of the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health.
NIDDK Clearinghouses Publications Catalog
5 Information Way
Bethesda, MD 20892–3568
Phone: 1–800–860–8747
TTY: 1–866–569–1162
Fax: 703–738–4929
Email: catalog@niddk.nih.gov

Privacy | Disclaimers | Accessibility | Public Use of Materials
H H S logo - link to U. S. Department of Health and Human Services NIH logo - link to the National Institute of Health NIDDK logo - link to the National Institute of Diabetes and Digestive and Kidney Diseases